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Abstract 
Background: The assessment of patient clinical outcome focuses on measuring various aspects of the health status 
of a patient who is under healthcare intervention. Patient clinical outcome assessment is a very significant process 
in the clinical field as it allows health care professionals to better understand the effectiveness of their health care 
programs and thus for enhancing the health care quality in general. It is thus vital that a high quality, informative 
review of current issues regarding the assessment of patient clinical outcome should be conducted. Aims & 
Objectives: 1) Summarizes the advantages of the assessment of patient clinical outcome; 2) reviews some of the 
existing patient clinical outcome assessment models namely: Simulation, Markov, Bayesian belief networks, 
Bayesian statistics and Conventional statistics, and Kaplan-Meier analysis models; and 3) demonstrates the 
desired features that should be fulfilled by a well-established ideal patient clinical outcome assessment model. 
Material & Methods: An integrative review of the literature has been performed using the Google Scholar to 
explore the field of patient clinical outcome assessment. Conclusion: This paper will directly support researchers, 
clinicians and health care professionals in their understanding of developments in the domain of the assessment 
of patient clinical outcome, thus enabling them to propose ideal assessment models. 
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Introduction  
In recent years, patient clinical outcome assessment 
in health care have been affirmed towards accurate 
judgment of the results of health care for patients 
who have undergoes under medical intervention. 
Patient clinical outcome will give health care 
professionals better understanding about the 
effectiveness of their health care programs and thus 
for improving the health care quality (1,2). 
Choosing a scale or model is the most important 
factor in choosing any therapeutic procedure; the 
model should fit its intended purposes. Although 
there are a considerable number of patient clinical 
outcome assessments models, it is important for 
researchers and health care professionals to 
understand that those models must satisfy a set of 
requirements to be used in medical field or any 
research related to clinical field. These requirements 
covers all portions of the instrument from the 
development of the model, measuring its properties, 
and interpretability to clinical usefulness from the 
patient’s point of view and the clinician’s point of 
view (1,2). There are eight criteria for selecting a 
Patient-based Outcome model. 
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1. Model development: A health professional 
should determine whether a systematic process 
was used in developing model or not. The first 
anxiety regarding any patient-based outcome 
model is the procedure used for developing it. 
Development of patient-based model is 
complex; and involves multiple stages such as: 
model substances generation, initial substance 
reduction, field testing and final substance 
reduction and finally, establishment of the 
properties of the scale measurement (1,2). 
2. Suitability: Suitability is how closely the model 
relates to a specific clinical situation (3). A health 
care professional should identify a particular 
purpose for the use of the scale, which should 
relate to the condition/disease or injury. A 
health care professional should determine 
whether the content of the model is appropriate 
for the clinical question, condition, or patient 
being treated, and whether the model is suitable 
for a variety of patients observed clinically (4). 
3. Reliability: to which degree does the model 
measures a case or score, as dissenting to 
random error. A health care professional should 
determine whether the results produced from 
the model consistent and stable. Stability can be 
measured through administration of the model 
on two separate periods, during an interval in 
which condition of the patients is unchanged 
(4,5,6). 
4. Validity: refers to the ability of the model to 
measure the scale or dimension that the model 
intended to measure (1). 
5. Responsiveness: A model is responsive if it is able 
to detect any changes over time as they occurred 
(4,5). Thus, the model measures improvement or 
deterioration patient’s condition once it 
happened. Responsiveness must not be 
discarded when selecting a model, because it 
might happen that a model is valid and reliable 
but not responsive. There are many ways to 
measure responsiveness such: change score, 
effect size (ES), standardized response mean 
(SRM), sensitivity and specificity to change, and 
receiver operating characteristics (6). 
6. Interpretability: The obtained score derived from 
a model is understandable easily by health care 
professionals. One critique of patient-based 
outcome models is that their scores are not as 
interpretable as other clinical measures, such as 
heart rate and blood pressure (1,4). To increase 
interpretability of models, it is important to 
report the minimal detectable change (MDC) 
and the minimal important difference (MID). 
7. Acceptability: means that is the model is 
acceptable by the patient, in other word can the 
model be completed in a short period of time 
and do its questions short, clear and easy to 
understand (4). Generally speaking, short 
questionnaires that are easy to read are 
accepted easily by the patients and provide a 
high response rate. 
8. Feasibility: refers to how easy the model to 
administer as part of the routine care delivery 
process (4,5). How much training time needed 
clinicians to administer the model and how much 
effort and cost needed to administer the model 
(4,5). 
In general, patient-based outcome assessment 
models are classified according to their field of use 
as either generic outcome models or specific 
outcome models; both have specific applications and 
limitations. Generic outcome models are more 
suitable for patient populations and injuries; they 
focused typically on Health-related quality of life 
(HRQoL) (7). On the other hand, specific outcome 
measures criteria or scale. 
 
This paper can lead to better understanding of 
developments in the assessment of patient clinical 
outcome domain. This paper will support 
researchers, clinicians and health care professionals 
in their: understanding of the advantages of the 
assessment of patient clinical outcome; 
understanding of some of the existing patient clinical 
outcome assessment models; and knowing the 
desired features that should be fulfilled by a well-
established ideal patient clinical outcome 
assessment model. Based on this study, researchers 
will be able to design ideal assessment models for 
patient clinical outcome that reserve the conceptual 
merits of existing models, avoid their limitations, and 
achieve the desired features of the existing models. 
Aims & Objectives 
1. To Summarizes the advantages of the 
assessment of patient clinical outcome. 
2. To Reviews some of the existing patient clinical 
outcome assessment models namely: 
Simulation, Markov, Bayesian belief network, 
Bayesian statistics and Conventional statistics, 
and Kaplan-Meier analysis models. 
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3. Describes the desired and ideal features that 
should be fulfilled by a well-established patient 
clinical outcome assessment model. 
Material & Methods 
An integrative review of the published literature 
(studies from 2000 to the present) using the Google 
Scholar database, due to its broader data coverage, 
has been performed. The key words Patient, Clinical 
Outcome, Assessment of Clinical Outcome, 
Healthcare, Assessment Model, Advantages of 
Assessment and similar pre-identified terms were 
used in separate searches and in conjunction with 
each other to identify all related publications. 
Related publications including papers, books and 
reports were evaluated and selected if they met a 
criteria of presenting information that authors 
believed could be accredited to the purpose of this 
study. The collected literature has been summarized 
and divided into the following sub-sections: 
1.1 Why the Assessment of Patient Clinical 
Outcome is Needed? 
 Monitoring and comparing the health 
status of different populations at 
different times (3, 8), tracking and 
comparing the performance of health 
professionals and organizations over 
time (9), identifying the best choice 
among therapeutic alternatives, and 
comparing different medicinal products 
(10,11). 
 Evaluation of health programs, health 
care interventions, different health 
conditions (9,12), and treatment efficacy 
in clinical trials (9,10) for health policy 
analysis, economic evaluation, and 
resource allocation (11). 
 For better communication of benefits 
and safety information of therapeutic 
alternatives (10,11,13) and to facilitate 
the sharing of information among 
regulatory agencies (14). 
 Prevent cognitive biases in making 
decisions. A conventional decision 
making is subjective, non-quantitative, 
sometimes inconsistent and lead to 
uncertainty in the effectiveness of the 
decisions (15). It is affected by cognitive 
biases (16). People will most often take 
decisions on intuitive or heuristic basis 
(17). This way of thinking prevent 
considering all options, outcomes, and 
probabilities at once (18,19). Different 
bias types are thoroughly discussed in 
the literature (19). 
 Improve healthcare decision making (17, 
20), increase transparency, consistency, 
and objectivity of regulatory decisions 
and recommendations (21), and protect 
patient’s safety (22). 
 Pharmaceutical development faces 
complex decisions that require tradeoffs 
between the desirable and undesirable 
effects of new therapies (23), and the 
existence of more standardized and 
quantifiable methods will encourage 
innovative drug development programs 
(24). 
1.2 Assessment Models for Patient Outcome 
There are a number of models, as shown in 
Table1, which have been employed for some 
role in the assessment of patient outcome. 
These models are Simulation, Markov 
model, Bayesian belief networks, Bayesian 
statistics, Conventional statistics, and 
Kaplan-Meier analysis (25). These models or 
techniques are nonspecific and used widely 
in the medical and other non-medical fields. 
1.2.1 Simulation Model 
Simulation is attempts to mimic the behavior 
of a system in reality, for example, a flight 
simulator mimics the behavior of an aircraft 
and used for training purposes (26). it is a 
methodical framework for generating the 
best available evidence about how the world 
works by joining knowledge and data from 
many diverse sources (26). it is used when 
direct implementation is impossible, to 
better understand and predict the future 
behavior of a system, and to aid in decision-
making (27). Simulation starts with a set of 
assumptions about the simulated system 
and resembles its functioning using some 
mathematical formulae (27). It offers the 
flexibility to characterize complex situations, 
incorporate time-dependent events and 
evaluate the consequences of a given 
strategy or set of strategies (27). it can be 
used to evaluate the cost-effectiveness of 
different clinical interventions and policy 
strategies (27). Simulation in healthcare 
decision problems has increased 
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considerably with the advances of 
computing power (27, 28). There are many 
simulation methods; for example, discrete 
event simulation (29), system dynamics 
simulation (27), probabilistic simulation, and 
Monte Carlo simulation (26, 27). 
1.2.2 Markov Model 
Markov model is useful when a decision 
problem involves exposure to risks or events 
over time, in which the specific timing of an 
event is uncertain (26). Markov model 
affords a way of modeling which evaluates 
clinical problems with ongoing risk. The 
model consists from Markov states, which 
represents the states of health of interest for 
patient who is transited from one state to 
another with transition probability (27). The 
states should be mutually exclusive, in which 
the patient cannot be in more than one state 
at a time (30, 31). Every state is assigned a 
utility scaled from zero to one, and the value 
of this utility depends on the length of time 
spent in the state. The time horizon of the 
analysis is divided into equal intervals of 
time, every interval is called as Markov cycle. 
The length of the cycle usually represents a 
clinically meaningful time interval. For a 
model that covers the entire life of a patient, 
the cycle length can be one year. During 
every cycle, the patient may move from one 
state to another. Every state is represented 
graphically by a circle. Circles are connected 
by arrows, and the direction of the arrow 
represents the transition from a state to 
another. Not all transition is allowed. For 
example, if there is three health states Well, 
Disabled, and Dead, the transition from 
Disabled to Dead is allowed while the 
transition from Dead to Disabled is not 
allowed. Arrows emanates from a state to 
itself show that the patient may remain in 
that state in many cycles. The resulting 
diagram is called a state-transition diagram 
(32). 
Markov process must have at least one state 
in which the patient cannot leave. These 
states are necessary for the process to 
terminate. Those states are called absorbing 
states and death is an example for an 
absorbing state (33). Markov models are 
mainly suitable to model chronic diseases 
(33). 
Markov models simply and directly can 
handle both costs and outcomes 
simultaneously (33). The summation of all 
state durations in which every state 
multiplied by its utility will yield the quality 
adjusted of life years (33). Cost-effectiveness 
could be performed for every cycle, state or 
for the entire lifetime of the model (33). 
1.2.3 Bayesian Belief Network Model 
A Bayesian belief network structure or 
causal networks is a finite directed acyclic 
graph composed from nodes and arcs, nodes 
represent the variables or events of concern, 
and arcs from parent nodes to child nodes 
represent a probabilistic relationship 
between the child and its parents. For 
example, one node could represent the 
benefits of a drug, and another node the 
risks (33). These probabilities represent the 
uncertainty of the relationships among the 
variables (26). This method is used for 
probabilistic inference in case of uncertainty 
(34) and translate information into 
dependence relations among variables 
under specified conditions (26). 
Bayesian belief network can calculate for the 
joint probability of combination of variable 
states (35). Building a Bayesian belief 
network structure includes the selection of 
relevant variables by experts, the 
identification of the relationships among the 
variables, the identification of qualitative 
logical and probabilistic constraints, the 
evaluation of probabilities, and sensitivity 
analysis and evaluation (34). Bayesian belief 
network can use different types of evidence 
including both objective data and expert 
judgments, change believes in the light of 
the new information and making predictions 
even with incomplete data (36). 
Bayesian belief network was used for the 
estimation of cause-specific mortality rates 
(37), the prediction of the outcome of 
disease and treatment (38), the diagnoses of 
disease, the selection among treatment 
alternatives, the construction of disease 
models, and in bioinformatics (39).  
1.2.4 Bayesian Statistics and Conventional 
Statistics Model 
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The probability of causal inference could be 
calculated mainly by two types of statistics, 
which are Bayesian and conventional 
statistics (36). A Bayesian statistics analysis 
uses a previous knowledge to form a prior 
probability distribution for the value of 
interest and adds new evidence, which is 
constituted by a model to produce a 
posterior probability distribution (40). 
Different experts will have different prior 
beliefs, and this issue will affect the posterior 
results, in this case, sensitivity analysis is 
performed to evaluate the effects on the 
posterior distributions of these different 
beliefs (41). 
Bayesian statistics is used widely in the 
medical statistics, including clinical trials, 
epidemiology, meta-analyses and evidence 
synthesis, molecular genetics and decision-
making for new technologies (41). Bayesian 
statistics is complex and requires advanced 
mathematical expertise and extensive 
computing power of hardware and software 
(42). 
 
In contrast to the previous approach, the use 
of prior information in conventional 
(frequentist) statistics tends to be 
unsystematic and informal (43), and 
introducing prior subjective assumptions 
into an inference is unpalatable to some 
statisticians (41). Conventional statistics 
uses only information obtained from the 
study, and does not include any prior 
information into the inferential process (44, 
45). 
1.2.5 Kaplan-Meier Survival Analysis Model 
Kaplan-Meier analysis is a measure for the 
fraction of subjects surviving or the 
probabilities of occurrence of an event for a 
certain amount of time after therapy (46). 
This method can also be used for any single 
measurable quantity of either undesired or 
desired effects to check the change over 
time of this effect (26, 47). Examples of 
events are myocardial infarction, recovery of 
renal function, first renal transplant, or time 
to discharge from hospital (26). The Kaplan-
Meier approach can evaluate the cumulative 
survival over time (48). If d subjects are 
surviving at the end of the time interval and 
n are the total number of subjects, then the 
estimated probability of surviving this 
interval is d/n (49). Total probability of 
survival until particular time interval is 
calculated by multiplying all earlier 
probabilities of survival for all preceding 
time intervals (47). Kaplan-Meier approach 
does not support multi-criteria analysis for 
many effects, nor include uncertainty (47, 
50) and it is not suitable to use for more than 
one competing risk (26,48). 
 
1.3 Desired Features of an Ideal Patient Clinical 
Outcome Assessment Model 
Based on the literature research of patient clinical 
outcome assessment models, we identify the 
following desired features that should be fulfilled by 
a well-established ideal patient clinical outcome 
assessment model. 
 An ideal model should first be clinically relevant 
(49). Main patient concerns seek components 
which are improved in the clinical setting. Also, 
the model should focus on fields under medical 
practitioner’s expertise. 
 Model assumptions should be disclosed and 
explicit (51). 
 Consistency: in which states that are logically 
worse or better must be reflected in the model 
(52), and intuitively reasonable to clinicians and 
researchers (53). It should make sense to anyone 
using it and be seen as a realistic way for 
evaluation. 
 Coherency: to ensure that model’s based 
decisions do not contradict each other or the 
objectives that are to be met (26). 
 Interpretability: which is the degree at which the 
meaning of quantitative scores can be easily 
understood (26). The outputs of the model 
should be understandable in quantitative form 
and interpretable in the user’s terms, to facilitate 
comparison between options (10, 11). 
 Answer important and practical clinical 
questions (26, 54), and the output of the model 
should lead clearly to action. 
 Be relatively simple (26). 
 The structure of a model should not be driven by 
the availability of data with which to populate 
the model (55). 
 The model should develop insight and promote 
learning about the evaluation process. It should 
also be easy to teach and use (56).  
INDIAN JOURNAL OF COMMUNITY HEALTH / VOL 28 / ISSUE NO 02 / APR – JUN 2016                                     [The Assessment of Patient]… |  Hourani M et al 
121 
 The model should provide a clear audit trail so 
that all aspects of the assessment process can be 
traced (26). 
 Be based upon the concept of health (26), and 
should consider quantitative aspects of health as 
the capacity for improving and maintaining 
health (57). It should also covers the domains of 
the ICF (58), exceeds ICF conceptual limitations, 
and covers domains which are clinically 
important and not covered by ICF. 
 Combines and includes all clinical heterogeneous 
components of benefits, harms and risks with 
different units and parameters using single scale 
(59). 
 The model’s results should not change relative 
evaluations when alternatives are added or 
removed (52). 
 The model’s values should be aggregated to 
evaluate the health system, state, and national 
health levels (51). 
 Sets a conception for weighting and trading off 
benefits and harms (60). This is still a difficulty, 
and this step is necessary to avoid the limitations 
of old methods. 
 Handles multiple benefits and harms 
concurrently (61). This is necessary to avoid the 
limitations of old methods. 
 The model should have the ability to be 
supported by computer software in which user 
can make changes quickly and get immediate 
feedback (62); so, the model could be used in 
everyday clinical practice through an operational 
system. 
 Used for any purpose, setting or population. This 
is necessary to avoid the limitations of old 
methods. 
 Flexible and adaptable (26), and allows 
assessment update as new information and 
therapy modalities become available (54). This is 
still a challenge in the clinical field. 
 Considers and recognizes time factor for both 
benefits and harms (63).  
 Considers natural history of the disease, natural 
history of the disease includes incidence or 
prevalence, extent of control or cure for disease, 
self-limiting conditions, chronic and progressive 
disease states, underlying disease with 
intermittent acute exacerbations, mortality, life 
expectancy, severity and seriousness of diseases 
and adverse events, and the times of events 
occurrences and their sequence. Also is should 
include emotional and psychiatric disorders. The 
desired method should provide a clinical 
numerical rather than subjective value. This is 
necessary to avoid the limitations of some old 
methods.  
 Handles patient health preferences through real 
rather than hypothetical clinical situations. This 
is necessary to avoid the limitations of old 
methods. 
 Patient health preferences should be time 
dependant (23), in which the model could track 
if patient preferences change with time. This is 
necessary to avoid the limitations of old 
methods. 
 Deals with both active and passive patients 
regarding their remedy. Both types of patients 
are handled in the clinical setting (26). 
 Considers the causality specially with the 
presence of comorbidities and concomitant 
therapies associated with patient disease (25). 
 Considers the strength or quality of the clinical 
evidence (64) 
Conclusion 
Patient outcome is the status upon a patient’s 
adherence to treatment, and is increasingly seen as 
significant for clinical adherence and uptake of 
healthcare interventions (65). Assessment of patient 
clinical outcome is one of the important aspects of 
patient safety, and requires the assessment of the 
benefits, harms and risks of therapeutic options and 
comparing between them. Qualitative, and 
quantitative models are developed for this process. 
However, very few models are developed for the 
clinical field and there is still a need for more 
accurate models for such evaluation.  
Recommendation 
Thus, it is very important for researchers, clinicians 
and health care professionals to understand the 
developments in the domain of the assessment of 
patient clinical outcome, thus enabling them to 
propose ideal assessment models. 
Relevance of the study 
This paper presents an informative review of current 
issues regarding the assessment of patient clinical 
outcome. First, it sums up the advantages of the 
assessment of patient clinical outcome. Then, it 
provides a review of a number of the existing patient 
clinical outcome assessment models, namely: 
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Simulation, Markov, Bayesian belief networks, 
Bayesian statistics and Conventional statistics, and 
Kaplan-Meier analysis models. Each model has been 
studied with emphasis on its usage in the medical 
assessment. Finally, based on the literature research 
of patient clinical outcome assessment models, it 
demonstrates the desired features that should be 
fulfilled by a well-established ideal patient clinical 
outcome assessment model. 
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